IG continues to be driven by a strong underlying volume demand and favorable pricing, especially outside U.S. Our subcutaneous immunoglobulin Xembify continues to see a strong volume up peak especially in Q3, backed by higher demand in the US.

Source: https://seekingalpha.com/article/4646966-grifols-s-grfs-q3-2023-earnings-call-transcript?source=feed_all_articles

Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.

Source: https://www.americanbankingnews.com/2023/01/23/andesa-financial-management-inc-has-74000-stake-in-pds-biotechnology-co-nasdaqpdsb.html